Table 1 Demographic data for the trial and control cohorts
Variable | NKP1 (n = 36) | Control cohort (n = 72) | |
|---|---|---|---|
Timings | |||
First CIT, hours, median (IQR) | 8.57 (3.49) | 8.88 (3.16) | |
Normothermic machine perfusion time, hours, median (IQR) | 5.83 (4.54) | - | |
Second CIT, minutes, median (IQR) | 68.41 (30.00) | - | |
Total preservation time, hours, median (IQR) | 15.74 (6.35) | 8.88 (3.16) | |
Recipients | |||
Age, years, mean (sd) | 59.2 (12.0) | 53.8 (14.4) | |
Sex, male, n (%) | 24/36 (67%) | 46/72 (64%) | |
BMI, mean (sd) | 28.1 (5.8) | 27.3 (5.1) | |
Dialysis modality, n (%) | HD | 22/36 (61%) | 46/72 (64%) |
PD | 10/36 (28%) | 9/72 (13%) | |
Predialysis | 4/36 (11%) | 17/72 (24%) | |
Duration of dialysis, years, mean (sd) | 2.3 (2.0) | 1.9 (2.2) | |
Previous transplant, n (%) | 8/36 (22%) | 12/72 (17%) | |
History of diabetes, n (%) | 12/36 (33%) | 12/72 (17%) | |
Induction immunosuppression, n (%) | Alemtuzumab | 26/36 (72%) | 52/72 (72%) |
Basiliximab | 10/36 (28%) | 20/36 (28%) | |
Donors | |||
Donor age, years, mean (sd) | 54.0 (15.8) | 55.0 (15.1) | |
Donor type, n (%) | DBD | 20/36 (56%) | 40/72 (56%) |
DCD | 16/36 (44%) | 32/72 (44%) | |
Donor sex, male, n (%) | 23/36 (64%) | 40/72 (56%) | |
Donor BMI, mean (sd) | 28.3 (6.4) | 27.3 (5.9) | |
Donor history of hypertension, yes, n (%) | 18/36 (50%) | 18/72 (25%) | |
Donor risk index (DRI), mean (sd) | 1.36 (0.59) | 1.35 (0.55) | |
HLAMM group, n (%) | 1 | 0/36 (0%) | 4/69 (6%) |
2 | 9/36 (25%) | 18/69 (26%) | |
3 | 19/36 (53%) | 28/69 (41%) | |
4 | 8/36 (22%) | 19/69 (28%) | |
